BioCryst Pharmaceuticals
BCRX
Market cap $1.72B

8.22 USD

+0.13

1.61%

At close Jul 30, 4:00 PM EDT

After hours

8.22

+0.00

0.00%

1 day

1.61%

5 days

-4.97%

1 month

-8.26%

3 months

-7.12%

6 months

4.45%

Year to date

4.98%

1 year

11.08%

5 years

94.79%

10 years

-46.41%

About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Employees: 580

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

99% more call options, than puts

Call options by funds: $9.58M | Put options by funds: $4.81M

78% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 23

64% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 67

5% more funds holding

Funds holding: 258 [Q4 2024] → 271 (+13) [Q1 2025]

2.45% more ownership

Funds ownership: 80.95% [Q4 2024] → 83.39% (+2.45%) [Q1 2025]

4% more capital invested

Capital invested by funds: $1.26B [Q4 2024] → $1.31B (+$52.8M) [Q1 2025]

40% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 3 (-2) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

34%

upside

Avg. target

$16.71

103%

upside

High target

$30

265%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

B of A Securities Tazeen Ahmad	82%upside $15	Buy Maintained	1 Jul 2025
RBC Capital Brian Abrahams	58%upside $13	Outperform Reiterated	30 Jun 2025
Wedbush Laura Chico	119%upside $18	Outperform Maintained	30 Jun 2025
Needham Serge Belanger	107%upside $17	Buy Reiterated	27 Jun 2025
Barclays Gena Wang	34%upside $11	Equal-Weight Maintained	7 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about BCRX published over the past 30 days

Zacks Investment Research

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst to Report Second Quarter 2025 Financial Results on August 4

RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.

BioCryst to Report Second Quarter 2025 Financial Results on August 4

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments.

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Zacks Investment Research

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development.

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from prior 2027 net cash guidance)— RESEARCH TRIANGLE PARK, N.C., June 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has entered into a definitive agreement to sell its European ORLADEYO® (berotralstat) business to Neopharmed Gentili for up to $264 million.

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Zacks Investment Research

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks Investment Research

5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility

INSW, ASR, BCRX, ASC and RRGB top the list of highly efficient stocks poised for gains amid market volatility.

5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility

Zacks Investment Research

New Strong Buy Stocks for June 25th

BILI, AEM, EVR, VEEV and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on June 25, 2025.

New Strong Buy Stocks for June 25th

See News Rankings

Charts implemented using Lightweight Charts™